tiprankstipranks
Advertisement
Advertisement

BMY Stock Latest News

Bristol-Myers Squibb Adds Early Alzheimer’s Antibody To Its Long-Term Growth Story
Company AnnouncementsBristol-Myers Squibb Adds Early Alzheimer’s Antibody To Its Long-Term Growth Story
1d ago
BMY
Bristol‑Myers Squibb Advances Navlimetostat Metabolism Study, Signaling Steady Pipeline Progress
PremiumCompany Announcements
Bristol‑Myers Squibb Advances Navlimetostat Metabolism Study, Signaling Steady Pipeline Progress
2d ago
BMY
Bristol-Myers Squibb: Late-Stage Pipeline Catalysts Support Buy Rating and Unchanged $80 Price Target
PremiumRatings
Bristol-Myers Squibb: Late-Stage Pipeline Catalysts Support Buy Rating and Unchanged $80 Price Target
3d ago
BMY
Bristol-Myers Squibb: Sell Rating Reiterated as Competitive Pressures Mount; $40 Price Target Unchanged Signaling Further Downside
PremiumRatings
Bristol-Myers Squibb: Sell Rating Reiterated as Competitive Pressures Mount; $40 Price Target Unchanged Signaling Further Downside
5d ago
BMY
Atrium Therapeutics earns $15M milestone payment from Bristol Myers
PremiumThe Fly
Atrium Therapeutics earns $15M milestone payment from Bristol Myers
6d ago
BMY
RNA
Court revives suit against Bristol Myers over delayed drug, Reuters reports
PremiumThe FlyCourt revives suit against Bristol Myers over delayed drug, Reuters reports
6d ago
BMY
UMBF
Bristol Myers’ first CELMoD myeloma therapy granted accelerated FDA approval
Premium
The Fly
Bristol Myers’ first CELMoD myeloma therapy granted accelerated FDA approval
6d ago
BMY
Balanced Risk-Reward Keeps Bristol-Myers Squibb at Hold as Zenbexus CELMoD Opportunity Awaits Key 2026 Data
Premium
Ratings
Balanced Risk-Reward Keeps Bristol-Myers Squibb at Hold as Zenbexus CELMoD Opportunity Awaits Key 2026 Data
9d ago
BMY
Bristol-Myers Squibb Expands Kidney Pipeline With New Golcadomide Renal Study
PremiumCompany Announcements
Bristol-Myers Squibb Expands Kidney Pipeline With New Golcadomide Renal Study
9d ago
BMY
BMY Expands Melanoma Immunotherapy Footprint With New Phase 4 Trial in India
PremiumCompany Announcements
BMY Expands Melanoma Immunotherapy Footprint With New Phase 4 Trial in India
10d ago
BMY
Investor backlash killed AstraZeneca, Bristol Myers tie-up, FT reports
PremiumThe Fly
Investor backlash killed AstraZeneca, Bristol Myers tie-up, FT reports
11d ago
AZN
BMY
Bristol Myers announces $2.3B campus in Houston, Texas
PremiumThe Fly
Bristol Myers announces $2.3B campus in Houston, Texas
12d ago
BMY
BlossomHill Therapeutics Stock (BLSM) Fails to Shine After $150M U.S. IPO
PremiumMarket NewsBlossomHill Therapeutics Stock (BLSM) Fails to Shine After $150M U.S. IPO
15d ago
BMY
JPM
Bristol-Myers Squibb Tracks Real-World Use of Luspatercept in Anemia Care
Premium
Company Announcements
Bristol-Myers Squibb Tracks Real-World Use of Luspatercept in Anemia Care
15d ago
BMY
Midday Fly By: SpaceX slips, Disney reports earnings beat
Premium
The Fly
Midday Fly By: SpaceX slips, Disney reports earnings beat
17d ago
BX
MS
No $400B Mega Merger? AstraZeneca Rises, Bristol Myers Falls as Report Denies Deal
PremiumMarket News
No $400B Mega Merger? AstraZeneca Rises, Bristol Myers Falls as Report Denies Deal
17d ago
AZN
BMY
Best Buy downgraded, Bristol Myers upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Best Buy downgraded, Bristol Myers upgraded: Wall Street’s top analyst calls
17d ago
AZN
BBY
Bristol Myers upgraded to Buy from Hold at Argus
PremiumThe Fly
Bristol Myers upgraded to Buy from Hold at Argus
17d ago
BMY
Bristol Myers, AstraZeneca not engaged in merger talks, Reuters reports
PremiumThe Fly
Bristol Myers, AstraZeneca not engaged in merger talks, Reuters reports
17d ago
AZN
BMY
Schrodinger announces collaboration, software agreement with Bristol Myers
PremiumThe FlySchrodinger announces collaboration, software agreement with Bristol Myers
17d ago
BMY
SDGR
AstraZeneca deal talks with Bristol Myers remain active, Semafor says
Premium
The Fly
AstraZeneca deal talks with Bristol Myers remain active, Semafor says
18d ago
AZN
BMY
TD Cowen sees no strategic logic in an AstraZeneca-Bristol Myers merger
Premium
The Fly
TD Cowen sees no strategic logic in an AstraZeneca-Bristol Myers merger
19d ago
AZN
BMY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >